-
公开(公告)号：US20230416721A1
公开(公告)日：2023-12-28
申请号：US18220864
申请日：2023-07-12
Inventor： Michael D. STORY , Narasimha Kumar KARANAM
Abstract: Methods of reducing survival of cancer cells in a subject by applying alternating electric fields to the cancer cells and delivering at least one of an E2F inhibitor and a CDK4/6 inhibitor to the cancer cells are provided. In some instances, alternating electric fields are applied to the cancer cells at a frequency between 80 and 300 kHz. In some instances, at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. In some aspects, the alternating electric fields are applied to the cancer cells for at least 72 hours.
-
公开(公告)号：US20230398539A1
公开(公告)日：2023-12-14
申请号：US18249864
申请日：2021-10-22
Inventor： Robert M. BACHOO , Digant P. DAVÉ
IPC: B01L3/00
CPC classification number: B01L3/502761 , B01L3/502707 , B01L2200/12 , B01L2300/0829 , B01L2200/025 , B01L2300/12 , B01L2200/0647
Abstract: A Cell Migration Assay Plates (CMAP) assembly for high throughput microfluidic migration assays and method of manufacturing thereof are provided. The CMAP assembly includes a top plate having a plurality of wells aligned with a bottom plate having a plurality of troughs. Each of the plurality of wells is defined at least in part by first and second reservoirs and a divisional wall extending between the reservoirs. The bottom plate is secured to the top plate to form a plurality of micro-channels, such that each one of the plurality of micro-channels is defined by a portion of one of the divisional walls and a portion of a corresponding one of the plurality of troughs. The plurality of micro-channels enable communication between the reservoirs and visualization of cells migrating through the micro-channels. In this manner, migration of cells through the micro-channels can be visualized for testing and screening applications.
-
公开(公告)号：US11838403B2
公开(公告)日：2023-12-05
申请号：US16845556
申请日：2020-04-10
Inventor： Alekhya Muthineni , Eugene John
CPC classification number: H04L9/0631 , G06F1/26
Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.
-
44.发明公开公开(公告)号：US20230349914A1
公开(公告)日：2023-11-02
申请号：US18029395
申请日：2021-09-30
Inventor： Tianshi LU , Tao WANG
CPC classification number: G01N33/6845 , G06N3/08 , G06N3/0455 , G16B40/20 , G16B15/30
Abstract: Neoantigens play a key role in the recognition of tumor cells by T cells. However, only a small proportion of neoantigens truly elicit T cell responses, and fewer clues exist as to which neoantigens are recognized by which T cell receptors (TCRs). To help determine the TCRs that interact with particular neoantigens, prediction models that predict TCR-binding specificities of neoantigens presented by different classes of major histocompatibility complex (MHCs) were developed. To confirm the applicability of the model to clinical settings, the prediction models were comprehensively validated by a series of analyses. The validated prediction models used a flexible transfer learning approach and differential learning schema to achieve highly accurate prediction of TCR binding specificity only using TCR sequence data, antigen sequence data, and MHC alleles.
-
公开(公告)号：US20230338411A1
公开(公告)日：2023-10-26
申请号：US18312305
申请日：2023-05-04
Inventor： Mirko Hennig , Vladimir Kharitonov , Brandon A. Wustman , Jackson Eby , Rumpa Bhattacharjee , Daniel Siegwart
IPC: A61K31/7115 , A61K47/28 , A61K47/24 , A61K9/127 , A61K9/51
CPC classification number: A61K31/7115 , A61K9/1272 , A61K9/51 , A61K47/24 , A61K47/28
Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
-
Patent Agency Ranking
公开(公告)号：US11795457B2
公开(公告)日：2023-10-24
申请号：US17486136
申请日：2021-09-27
Inventor： David Corey , Liande Li
IPC: C07H21/04 , C12N15/113 , A61P25/00 , A61K45/06
CPC classification number: C12N15/113 , A61K45/06 , A61P25/00 , C12N2310/14 , C12N2310/315 , C12N2310/3231
Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.
-
公开(公告)号：US20230302138A1
公开(公告)日：2023-09-28
申请号：US18311616
申请日：2023-05-03
Inventor： Mirko Hennig , Vladimir Kharitonov , Brandon A. Wustman , Jackson Eby , Rumpa Bhattacharjee , Daniel Siegwart
CPC classification number: A61K47/543 , C12N15/113 , A61K47/544 , A61K47/10 , A61K47/28 , A61K9/0073 , A61P11/00
Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
-
公开(公告)号：US20230301988A1
公开(公告)日：2023-09-28
申请号：US18023661
申请日：2021-08-26
Inventor： Thomas D. Meek , Chien-Te Tseng , Aleksandra Drelich , Drake M. Mellott
IPC: A61K31/495 , A61P31/14 , G01N33/569
CPC classification number: A61K31/495 , A61P31/14 , G01N33/56983 , G01N2333/165
Abstract: Provided herein are pharmaceutical compositions including compounds having Formula I (I) in an effective amount to inhibit non-viral cysteine protease (e.g., mammalian cysteine protease, such as human cathepsin L), as well as methods of using thereof.
-
公开(公告)号：US20230235055A1
公开(公告)日：2023-07-27
申请号：US18007185
申请日：2021-07-26
Inventor： Zhiqiang AN , Chengcheng ZHANG , Ningyan ZHANG , Yuanzhi CHEN , Heyu CHEN
IPC: C07K16/28 , A61K45/06 , G01N33/574 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2803 , A61K45/06 , G01N33/57484 , A61K39/3955 , A61P35/00 , C07K2317/21 , C07K2317/24 , C07K2317/73 , A61K2039/505
Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
-
公开(公告)号：US11690545B2
公开(公告)日：2023-07-04
申请号：US16357990
申请日：2019-03-19
Inventor： Christopher John Zahner
IPC: A61B5/15 , B01F13/00 , B01F11/00 , B01L3/00 , A61J1/05 , B01F31/60 , B01F33/301 , B01F101/23
CPC classification number: A61B5/150755 , A61B5/150022 , A61B5/150206 , A61B5/150343 , A61J1/05 , B01F31/60 , B01F33/3017 , B01L3/00 , B01F2101/23
Abstract: In one embodiment, a mixing device includes a sleeve that forms an inner space configured to receive a sample container, a housing associated with the sleeve, a mixing element contained within the housing that is configured to mix liquid contained within the sample container, and an activation element configured to activate the mixing element when the activation element is triggered.
-
-
-
-
-
-
-
-
-
Search Results
1244
records
(took 0.059 seconds)
